Penumbra, Inc. (PEN)
USD 238.9
(-3.49%)
USD 238.9
(-3.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 590.87 Million USD | 11.67% |
| 2022 | 529.12 Million USD | 9.58% |
| 2021 | 482.88 Million USD | 28.05% |
| 2020 | 377.11 Million USD | 16.23% |
| 2019 | 324.45 Million USD | 23.58% |
| 2018 | 262.55 Million USD | 21.56% |
| 2017 | 215.97 Million USD | 25.44% |
| 2016 | 172.17 Million USD | 43.63% |
| 2015 | 119.87 Million USD | 50.16% |
| 2014 | 79.83 Million USD | 35.31% |
| 2013 | 59 Million USD | 29.58% |
| 2012 | 45.53 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 166.55 Million USD | 9.6% |
| 2024 Q3 | 164.94 Million USD | 0.35% |
| 2024 Q2 | 164.35 Million USD | -1.32% |
| 2023 Q1 | 143.06 Million USD | 7.09% |
| 2023 Q2 | 148.97 Million USD | 4.13% |
| 2023 Q4 | 151.96 Million USD | 3.46% |
| 2023 Q3 | 146.87 Million USD | -1.41% |
| 2023 FY | 590.87 Million USD | 11.67% |
| 2022 Q3 | 129.89 Million USD | -3.19% |
| 2022 Q4 | 133.59 Million USD | 2.85% |
| 2022 FY | 529.12 Million USD | 9.58% |
| 2022 Q1 | 131.46 Million USD | -20.57% |
| 2022 Q2 | 134.17 Million USD | 2.06% |
| 2021 Q1 | 97.87 Million USD | 1.89% |
| 2021 Q2 | 108.37 Million USD | 10.73% |
| 2021 Q3 | 111.13 Million USD | 2.54% |
| 2021 FY | 482.88 Million USD | 28.05% |
| 2021 Q4 | 165.5 Million USD | 48.93% |
| 2020 Q2 | 82.57 Million USD | -5.51% |
| 2020 FY | 377.11 Million USD | 16.23% |
| 2020 Q4 | 96.05 Million USD | -13.52% |
| 2020 Q3 | 111.08 Million USD | 34.51% |
| 2020 Q1 | 87.39 Million USD | -0.17% |
| 2019 Q4 | 87.54 Million USD | 5.45% |
| 2019 Q3 | 83.02 Million USD | 2.34% |
| 2019 Q2 | 81.12 Million USD | 11.5% |
| 2019 Q1 | 72.75 Million USD | 0.99% |
| 2019 FY | 324.45 Million USD | 23.58% |
| 2018 Q4 | 72.04 Million USD | 10.79% |
| 2018 Q2 | 62.96 Million USD | 0.73% |
| 2018 Q1 | 62.51 Million USD | 4.41% |
| 2018 FY | 262.55 Million USD | 21.56% |
| 2018 Q3 | 65.02 Million USD | 3.27% |
| 2017 FY | 215.97 Million USD | 25.44% |
| 2017 Q4 | 59.87 Million USD | 10.68% |
| 2017 Q3 | 54.09 Million USD | 3.52% |
| 2017 Q2 | 52.25 Million USD | 5.03% |
| 2017 Q1 | 49.75 Million USD | 4.24% |
| 2016 Q3 | 44.23 Million USD | 4.98% |
| 2016 Q1 | 38.07 Million USD | 9.91% |
| 2016 Q2 | 42.14 Million USD | 10.69% |
| 2016 Q4 | 47.73 Million USD | 7.9% |
| 2016 FY | 172.17 Million USD | 43.63% |
| 2015 Q1 | 22.73 Million USD | -3.53% |
| 2015 FY | 119.87 Million USD | 50.16% |
| 2015 Q4 | 34.63 Million USD | 10.61% |
| 2015 Q3 | 31.31 Million USD | 0.41% |
| 2015 Q2 | 31.18 Million USD | 37.16% |
| 2014 Q4 | 23.56 Million USD | 15.05% |
| 2014 Q2 | 20.22 Million USD | 29.2% |
| 2014 FY | 79.83 Million USD | 35.31% |
| 2014 Q3 | 20.48 Million USD | 1.32% |
| 2014 Q1 | 15.65 Million USD | 0.0% |
| 2013 FY | 59 Million USD | 29.58% |
| 2012 FY | 45.53 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott Laboratories | 15.71 Billion USD | 96.239% |
| Allurion Technologies Inc. | 120.57 Million USD | -390.049% |
| Artivion, Inc. | 223.43 Million USD | -164.453% |
| Avanos Medical, Inc. | 375.5 Million USD | -57.357% |
| Butterfly Network, Inc. | 162.46 Million USD | -263.693% |
| Butterfly Network, Inc. | 162.46 Million USD | -263.693% |
| Bio-Rad Laboratories, Inc. | 1.04 Billion USD | 43.594% |
| Boston Scientific Corporation | 7.47 Billion USD | 92.098% |
| Perspective Therapeutics, Inc. | 17.42 Million USD | -3290.778% |
| CONMED Corporation | 564.24 Million USD | -4.72% |
| Edwards Lifesciences Corporation | 3.09 Billion USD | 80.883% |
| Paragon 28, Inc. | 210.1 Million USD | -181.236% |
| Glaukos Corporation | 367.83 Million USD | -60.636% |
| Globus Medical, Inc. | 887.16 Million USD | 33.397% |
| Inspire Medical Systems, Inc. | 568.49 Million USD | -3.937% |
| Integer Holdings Corporation | 250.95 Million USD | -135.448% |
| Medtronic plc | 16.12 Billion USD | 96.337% |
| Nevro Corp. | 389.36 Million USD | -51.753% |
| Owlet, Inc. | 51.21 Million USD | -1053.629% |
| Vicarious Surgical Inc. | 80.66 Million USD | -632.498% |
| Smith & Nephew plc | 3.46 Billion USD | 82.957% |
| Sonendo, Inc. | 68.46 Million USD | -763.035% |
| STERIS plc | 1.4 Billion USD | 57.805% |
| Stryker Corporation | 9.2 Billion USD | 93.584% |
| Vapotherm, Inc. | 66.02 Million USD | -794.929% |
| Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 81.963% |